PMID- 21761190
OWN - NLM
STAT- MEDLINE
DCOM- 20120711
LR  - 20220408
IS  - 1434-4726 (Electronic)
IS  - 0937-4477 (Print)
IS  - 0937-4477 (Linking)
VI  - 269
IP  - 2
DP  - 2012 Feb
TI  - Liposomes: a new non-pharmacological therapy concept for 
      seasonal-allergic-rhinoconjunctivitis.
PG  - 495-502
LID - 10.1007/s00405-011-1696-6 [doi]
AB  - Mucosal barrier disorders play an important role in the pathomechanism of the 
      allergic disease. A new approach for their treatment uses liposomes, which 
      consist of phospholipids that make up 75% of the protective nasal surfactant 
      layer. Our aim was to investigate the efficacy of liposomal-based therapy, as a 
      comprehensive treatment alternative to guideline cromoglycate-based therapy, in 
      the treatment of seasonal allergic rhinoconjunctivitis (SAR). We compared nasal 
      and conjunctival symptom reduction with LipoNasal n nasal spray used as 
      monotherapy (LNM), or LipoNasal n nasal spray and Tears Again eye spray 
      combination therapy (LTC), against standard cromoglycate combination therapy 
      (CGC). This prospective, controlled, open observational study was conducted 
      monocentrically. According to their symptoms and preferences 72 patients with SAR 
      were distributed in three equal groups. The study comprised two visits at an 
      interval of 7 days. The efficacy was examined by daily documenting nasal and 
      conjunctival symptom scores. The Nasal-Spray-Sensory-Scale and the 
      Eye-Drops/Spray-Sensory-Scale were used to investigate the tolerability. Quality 
      of life (QoL) was evaluated, using the RHINASTHMA QoL German adapted version. LNM 
      achieved significant improvement in nasal (p < 0.001) and conjunctival symptoms 
      (p = 0.050). The symptom reduction using CGC was equally significant. LTC led to 
      significant nasal symptom relief (p = 0.045). QoL did not improve significantly 
      in all groups (p > 0.05). The tolerability of all treatments was good and no 
      adverse reactions were observed. In all treatment groups the improvement of the 
      nasal and conjunctival symptom scores exceeds the minimal clinically important 
      difference (MCID). The results demonstrate good tolerability and efficacy of 
      non-pharmaceutical liposomal-based treatment (LipoNasal n and Tears Again), given 
      as monotherapy or combination therapy, for nasal and conjunctival symptoms caused 
      by SAR. This study indicates that liposomal-based treatment for SAR may be a 
      comparable alternative to cromoglycate therapy. Further studies are needed to 
      verify these findings.
FAU - Bohm, M
AU  - Bohm M
AD  - Institute of Medical Statistics, Informatics and Epidemiology (IMSIE), University 
      of Cologne, 50924, Cologne, Germany.
FAU - Avgitidou, G
AU  - Avgitidou G
FAU - El Hassan, E
AU  - El Hassan E
FAU - Mosges, R
AU  - Mosges R
LA  - eng
PT  - Comparative Study
PT  - Controlled Clinical Trial
PT  - Journal Article
DEP - 20110715
PL  - Germany
TA  - Eur Arch Otorhinolaryngol
JT  - European archives of oto-rhino-laryngology : official journal of the European 
      Federation of Oto-Rhino-Laryngological Societies (EUFOS) : affiliated with the 
      German Society for Oto-Rhino-Laryngology - Head and Neck Surgery
JID - 9002937
RN  - 0 (Anti-Asthmatic Agents)
RN  - 0 (Liposomes)
RN  - 0 (Nasal Sprays)
RN  - 0 (Ophthalmic Solutions)
RN  - Q2WXR1I0PK (Cromolyn Sodium)
SB  - IM
MH  - Adolescent
MH  - Adult
MH  - Aged
MH  - Anti-Asthmatic Agents/administration & dosage
MH  - Conjunctivitis, Allergic
MH  - Cromolyn Sodium/administration & dosage
MH  - Drug Therapy, Combination
MH  - Female
MH  - Humans
MH  - Liposomes/*administration & dosage
MH  - Male
MH  - Middle Aged
MH  - Nasal Sprays
MH  - Ophthalmic Solutions
MH  - Rhinitis, Allergic, Seasonal
MH  - Time Factors
MH  - Treatment Outcome
MH  - Young Adult
PMC - PMC3259398
EDAT- 2011/07/16 06:00
MHDA- 2012/07/12 06:00
PMCR- 2011/07/15
CRDT- 2011/07/16 06:00
PHST- 2010/11/15 00:00 [received]
PHST- 2011/06/24 00:00 [accepted]
PHST- 2011/07/16 06:00 [entrez]
PHST- 2011/07/16 06:00 [pubmed]
PHST- 2012/07/12 06:00 [medline]
PHST- 2011/07/15 00:00 [pmc-release]
AID - 1696 [pii]
AID - 10.1007/s00405-011-1696-6 [doi]
PST - ppublish
SO  - Eur Arch Otorhinolaryngol. 2012 Feb;269(2):495-502. doi: 
      10.1007/s00405-011-1696-6. Epub 2011 Jul 15.